Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 356 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Polyethylene glycol Clear all
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

NCT02883049
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia, Testicular Leukemia
Interventions
Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 31 Years
Enrollment
5,949 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
209
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 21, 2026, 5:51 PM EDT
Not listed Phase 2Phase 3 Interventional

A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

NCT05660447
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Interventions
Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Not applicable Interventional Results available

Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes

NCT00096135
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, therapeutic hydrocortisone, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
18 Months to 29 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
135
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 116 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Results available

Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

NCT00075725
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
3,154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
208
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects

NCT01010282
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Glycerin and Polysorbate 80 based artificial tear, Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear, Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2015 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 4 Interventional

A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children

NCT00319670
View directory record Official record
Conditions
Constipation
Interventions
MiraLax
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
4 Years to 16 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Boston, Massachusetts • Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Not applicable Interventional Results available

DuraSeal Sealant Post Market Study

NCT00704340
View directory record Official record
Conditions
Elective Cranial Procedures With Dural Incision
Interventions
DuraSeal Dural Sealant System, Standard of Care
Device · Other
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Oct 21, 2026, 5:51 PM EDT
Terminated No phase listed Observational

EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment

NCT01582568
View directory record Official record
Conditions
Crohns Disease
Interventions
Certolizumab
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 21, 2026, 5:51 PM EDT
Recruiting Phase 2 Interventional

IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

NCT03152058
View directory record Official record
Conditions
High Risk Pregnancy, Pregnancy Complications, Antiphospholipid Syndrome in Pregnancy, Lupus Anticoagulant Disorder
Interventions
Certolizumab Pegol
Drug
Lead sponsor
David Ware Branch
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
New York, New York • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 21, 2026, 5:51 PM EDT
Terminated Phase 3 Interventional Results available

Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease

NCT00349752
View directory record Official record
Conditions
Crohn's Disease
Interventions
certolizumab pegol 400 mg, Placebo
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
54
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 1 Interventional

Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

NCT01403415
View directory record Official record
Conditions
Childhood B Acute Lymphoblastic Leukemia, Childhood T Acute Lymphoblastic Leukemia, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma
Interventions
Dexamethasone, Laboratory Biomarker Analysis, Methotrexate, Mitoxantrone Hydrochloride, Pegaspargase, Pharmacological Study, Temsirolimus, Vincristine Sulfate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2015 · Synced Oct 21, 2026, 5:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Polyethylene Glycol Safety in Children

NCT05424757
View directory record Official record
Conditions
Polyethylene Glycols, Children, Only
Interventions
PEG 3350
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
0 Years to 16 Years
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 4 Interventional Results available

A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy

NCT00708201
View directory record Official record
Conditions
Postoperative Ileus
Interventions
Alvimopan, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
20
States / cities
Laguna Hills, California • Aurora, Colorado • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2016 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Contraceptive Efficacy & Safety of Phexxi™ (Previously Known as Amphora) Gel Compared to Conceptrol Vaginal Gel

NCT01306331
View directory record Official record
Conditions
Contraception
Interventions
Conceptrol, Amphora
Drug
Lead sponsor
Evofem Inc.
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
3,389 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
41
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 4 Interventional Results available

COMFORT: A Multicenter, Open-label, Randomized, Crossover Study

NCT02462720
View directory record Official record
Conditions
Varicose Veins
Interventions
Varithena®, Radiofrequency ablation
Drug · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Pensacola, Florida • Melrose Park, Illinois • Amherst, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Not applicable Interventional Results available

NeoMend ProGEL™ Pleural Air Leak Sealant Post-Approval Study

NCT01394978
View directory record Official record
Conditions
Lung Cancer, Lung Tumor
Interventions
Control, ProGEL Pleural Air Leak Sealant with standard surgical closure, ProGEL Pleural Air Leak Sealant without standard surgical closure
Other · Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
18
States / cities
Birmingham, Alabama • Jacksonville, Florida • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2605541 in Healthy Participants

NCT01877265
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY2605541
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality

NCT00622037
View directory record Official record
Conditions
Dry Eye
Interventions
PEG-400 based artificial tear, Systane
Drug
Lead sponsor
Bp Consulting, Inc
Network
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 1 Interventional

ADI-PEG in Patients With Metastatic Melanoma

NCT00029900
View directory record Official record
Conditions
Melanoma, Neoplasm Metastasis
Interventions
ADI PEG
Drug
Lead sponsor
FDA Office of Orphan Products Development
Federal
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Results available

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis

NCT00717236
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab pegol (CZP), Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
1,648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
101
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Results available

Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis

NCT01087762
View directory record Official record
Conditions
Spondyloarthropathies
Interventions
CZP 200 mg Q2W, CZP 400 mg Q4W, Placebo
Biological · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
32
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Immunogenicity Study Comparing TPI-120 to Neulasta® in Healthy Adult Subjects

NCT03202927
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PEGFILGRASTIM
Drug
Lead sponsor
Adello Biologics, LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 2 Interventional

A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes

NCT04956263
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Type1diabetes, Diabetes Mellitus
Interventions
YG1699, Dapagliflozin
Drug
Lead sponsor
Youngene Therapeutics Inc., Ltd.
Industry
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 4 Interventional Results available

Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity

NCT01707667
View directory record Official record
Conditions
Chronic Constipation
Interventions
prucalopride, PEG 3350
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 21, 2026, 5:51 PM EDT